1
|
Bader S, Abbes W, Mahdhaoui W, Tfifha M, Rjeb I, Ghanmi L. Sociodemographic and clinical profile of attempted suicide patients. Eur Psychiatry 2021. [PMCID: PMC9479779 DOI: 10.1192/j.eurpsy.2021.1569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Suicide attempts are common and constitute a serious problem for public health.Thus, it is very important to evaluate risk factors for suicidal behavior. Objectives The purpose of this study was to explore the socio-demographic and clinical profile of attempted suicide patients consulting in the psychiatry department in Gabes (southern of Tunisia). Methods It was a retrospective descriptive and analytical study covering all patients who had attempted suicide during the period from the 1st of May, 2009 to September 25th, 2020 and who were referred to the psychiatry department in the regional hospital of Gabes. Sociodemographic and clinical data of the patients as well as characteristics of the suicide attemptswere assessed. Results Socio-demographic profile of the suicidal consultant in psychiatry department corresponded to a single (73.4%) female (78.8%), with a mean age of 26 years, from an urban area (46%). Suicide attempts were most often by the intentional drug ingestion (67.8%), committed between March and August in 54% of cases. At most of the time, the suicidal person was alone (85%) at home (94%) when he committed his suicidal attempt. He did not communicate his intention to commit suicide in 46% of the cases and only 22 cases (7.9%) notified a person before the suicide attempt and 12.6% afterwards. Suicide behavior was impulsive in 79.5% of the cases and a verbal expression of a desire to die was only noted in 24.5% of cases. Conclusions Our results suggest a systematic and specific psychiatric evaluation of any patient who attempts suicide. Conflict of interest No significant relationships.
Collapse
|
2
|
Bader S, Ellouz E, Abderrahim R, Abbas M, Mdhaffer K. Socio-demographic and clinical features of patients with dementia attended in the psychiatry department. Eur Psychiatry 2021. [PMCID: PMC9480426 DOI: 10.1192/j.eurpsy.2021.1971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
IntroductionDementia’s prevalence increases due to population aging, it has become a major public health concern.ObjectivesTo estimate the incidence of dementia and to describe the socio-demographic and clinical profile of patients attended in the psychiatry department of Gabes (Southern of Tunisia).MethodsIt was a retrospective descriptive study including all the patients who attended for the first time in the psychiatry department of Gabes, from the 1st January, 2010 to December 31, 2018, and who were diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Socio-demographic and clinical data were assessed. The Mini Mental State Examination (MMSE) was used as a neuropsychological examination.ResultsWe included 98 patients. The mean annual hospital incidence of dementia was 2.38%. The mean age was 76.5 ± 9.8 years. Patients were married (68%), illiterate (68%) and jobless (42.9%). A family history of dementia was noted in 39.8% of patients. The common cardiovascular comorbidity was high blood pressure (41.8%). Among our patients, 30 (30.6%) were smokers. The mean age of onset of dementia was 73 ± 11 years. The mean duration of untreated dementia was 3 years [3 months to 11 years]. First symptoms were mainly memory disorders (57.3 %) and behavioral disorders (17.3%) The mean MMSE score was 14 ± 4.8. Alzheimer’s disease was the most frequent etiology of dementia (80 cases, 82.7%).ConclusionsOur study shows a high incidence of dementia and made it possible to draw up a socio-demographic and clinical profile of dementia patients.DisclosureNo significant relationships.
Collapse
|
3
|
Bader S, Abbes W, Mahdhaoui W, Ltaif W, Ghanmi L. Vaginismus: Sociodemographic profile and cultural aspects. Eur Psychiatry 2021. [PMCID: PMC9471762 DOI: 10.1192/j.eurpsy.2021.859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
IntroductionVaginismus is the most common reason for unconsummated marriages in Tunisia.ObjectivesTo describe the socio-demographic profile and to explore the clinical and cultural aspects of sexual functioning of women with vaginismus.MethodsIt was a cross-sectional study established over a period of 3 months from the November 1st, 2019 to January 31st, 2020. This study focused on a population of women with vaginismus recruited from outpatient consultations of the hospital’s gynecology and psychiatry departments at the regional hospital of Gabes. We used a pre-established sheet exploring socio-demographic data, medical and gyneco-obstetric history and informations concerning the partner, the marital relationship and the woman’s sexual activity.Results35 women were included. They had a mean age of 30 years, jobless (54.5%) and with a secondary or university education (91.1%). The mean duration of marriage was 2.4 years. Partner had mean age of 36 and suffering from sexual dysfunction (21.3%). Among women, 12.5% had been sexually abused, 51.6% had suffered “Tasfih”, 70% had attended discussions about painful defloration. Vaginismus was primary in 85.7% and total in 50% of the cases. About the received thoughts of the women, 40% thought that vaginismus requires medical treatment, 13 of them (40%) thought that the disorder could be resolved spontaneously and 20% believed in a story of witchcraft. 85% consulted a physician and 24.2% a traditional therapist.ConclusionsVaginismus seems to be influenced by psychological and sociocultural factors so that a good psychoeducation of brides could reduce the incidence of this sexual disorder.Conflict of interestNo significant relationships.
Collapse
|
4
|
Bader S, Abbes W, Tfifha M, Dhemaid M, Mahdhaoui W, Ghanmi L. Warning signs of suicide attempts and risk of suicidal recurrence. Eur Psychiatry 2021. [PMCID: PMC9480028 DOI: 10.1192/j.eurpsy.2021.1571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Detecting warning signs of suicide attempts is a particular difficult task. However, people who plan to commit suicide almost always announce it to someone in some way. Objectives Aims of this study were to describe signs preceding the suicide attempt in a group of suicidal persons and its links with suicidal recurrence. Methods It was a retrospective study that included all the patients who attempted suicide during the period from May 1st, 2009 to September 25th, 2020 and who were referred to the psychiatry department of the regional hospital of Gabes. Sociodemographic and clinical data as well as suicidal attempts characteristics were assessed. Results 278 patients were included (female=78.1%), with mean age of 26. The common suicidal attempt method was intentional drug intoxication (67.8%). At least, one clinical manifestation was reported by 75.2% of suicide patients. The most common signs were the tendency to isolation (47.1%), a change in character or behavior (46.6%), thoughts of death (29.6%), anxiety or agitation (24.8%) and recent worsening of the pre-existing psychiatric symptoms (24.3%). Suicidal recurrence affected 24.8% of patients. It was correlated to the presence of a mental disorder (p<10-3), the presence of reflections on death (p=0.02), the onset of a state of anxiety or agitation (p<10-3), recent worsening of pre-existing psychiatric symptoms (p = 0.001) and verbal expression of suicidal thoughts (p<10-3). Conclusions The pre-suicidal syndrome is frequently heralded by changes in the patient’s character or behavior. Some suicidal warning signs are associated with the risk of suicidal recurrence. Conflict of interest No significant relationships.
Collapse
|
5
|
Dhemaid M, Abbes W, Kerkeni A, Bader S, Abbes M, Medhaffer K, Zitoun K, Ghanmi L. Covid19 pandemic impacts on mental health of tunisian health care workers. Eur Psychiatry 2021. [PMCID: PMC9471482 DOI: 10.1192/j.eurpsy.2021.771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction
Covid19 pandemic in Tunisia has disturbed the health system. Health care workers, who were in the frontline to face this disease, had experienced reactions of anxiety, depression and distress. Objectives To assess the level of anxiety and depression among health care workers of regional hospital of Gabes (south of Tunisia) and its associated factors. Methods
We conducted a cross-sectional study, from April 19, 2020, to May 5, 2020 on healthcare workers in Gabes regional Hospital. All hospital departments and units were included. We used a self-administered anonymous questionnaire containing sociodemographic and clinical data. Hospital Anxiety and Depression Scale (HAD) validated in the Tunisian dialectal version was used to assess anxiety and depression. Results Among the 289 responding participants, 100 (34.6%) were frontline health care workers directly engaged in managing patients with coronavirus disease. Our study revealed that 43.6% of health care workers were suffering from anxiety and 44.3 % from depression. There was a significant association between anxiety and female gender (p<0.001), being married (p=0.006), mental health conditions (p<0.001) especially anxiety disorders (p<0.001) and depressive disorders (p=0.03), personal medical history of dysthyroidism (p=0.013) and smoking (p=0.005). Nurses experienced more likely anxiety symptoms than other occupation (p=0.021). There was significant relationship between depression and female gender (p<0.001), married status (p=0.02), age under 50 (p=0.032) and mental health conditions (p<0.001) such as anxiety disorders (p=0.001) and depressive disorders (p=0.013). Conclusions It is crucial to provide care for health care workers with mental health problems during their struggle with covid19.
Collapse
|
6
|
Bader S, Abbes W, Sellami I, Falah WE, Hajjaji M, Ghanmi L. Sleep disorders among health care workers practicing in emergency department in south tunisia. Eur Psychiatry 2021. [PMCID: PMC9476048 DOI: 10.1192/j.eurpsy.2021.1480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Sleep disorders are the most common health problem among the health care staff, mainly those who perform night shifts. Objectives To assess the prevalence of sleep disorders among health care workers in emergency department and to determine its associated factors. Methods It was a cross-sectional study, including health care workers assigned to emergency ward and intensive care unit of Hedi Chaker and Habib Bourguiba hospitals in Sfax and regional hospital of Kebili, during the first six months of 2017. We used an anonymous and confidential self-administered questionnaire. We used hospital anxiety and depression scale (HAD) to assess anxiety and depression. Sleep quality was assessed by the Pittsburgh Sleep Quality Index and day time sleepiness by the Epworth Sleepiness Scale. Results 240 nurses were included. Mean age was 37 years-old, 59.2% were female and 64.2% were married and 79.2% assured night shifts. The prevalence of sleep disorders was 70.4%. Sleep difficulties were significantly correlated with anxiety (p=0.001) and depression (p=0.02). In multivariate study, sleep disorders were related to the absence of leisure activity (OR=0.42 [0.19-0.94]; p=0.035) and anxiety (OR=3 [1.4-6.1]; p=0.002). 40.8% of nurses experienced drowsiness. Sleepiness was significantly correlated with the absence of leisure activities (p=0.04) and with psychiatric family history (p=0.02). In the multivariate study, sleep disorders were correlated with female gender (OR=0.43 [0.19-0.9]; p=0.042) and with no leisure activity (OR=2.6 [1.2-5.6]; p=0.01). Conclusions Sleep disorders were common among emergency nurses, in order of that; working conditions should be improved to provide less stressful conditions for nurses. Conflict of interest No significant relationships.
Collapse
|
7
|
Troestler J, Parco C, Brockmeyer M, Lin Y, Krieger T, Quade J, Bader S, Kosejian L, Karathanos A, Heinen Y, Schulze V, Icks A, Kelm M, Wolff G. Standardized risk management in catheterization procedures for non-ST-segment elevation myocardial infarction: associations with in-hospital clinical outcomes. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction and purpose
Patient risk in non-ST-segment elevation myocardial infarction (NSTEMI) depends on clinical setting, individual patient variables and procedural characteristics. Standardized risk-adjusted periprocedural management for catheterization procedures using a Standard Operating Procedure (SOP) was investigated to evaluate associations with in-hospital clinical outcomes.
Methods
In 01/2018, our heart center established an SOP for coronary catheterization procedures in NSTEMI, targeting 1) standardized pre-procedural risk assessment using National Cardiovascular Data Registry (NCDR) risk models, and 2) standardized post-procedural risk-adjusted safety measures, including advanced patient monitoring (intermediate/intensive care) and use of vascular closure devices. All patients presenting with invasively-managed NSTEMI in 2018 were retrospectively evaluated for SOP-based pre-procedural risk scoring, SOP-based post-procedural management and in-hospital clinical outcomes of mortality, major bleeding (MB, according to BARC ≥3) and acute kidney injury (AKI, according to KDIGO).
Results
A total of 430 patients (age 72±12 years, 71% male, BMI 27±5) presenting with NSTEMI from 01 to 12/2018 were included, 9.8% presented in cardiogenic shock and 4.7% had suffered a preclinical cardiac arrest. Overall in-hospital mortality was 3.7%, MB occurred in 6.5%. 207 patients (48.1%, SOP+ group) had received both 1) pre-procedural risk assessment and 2) post-procedural risk-adjusted safety measures; the other 223 patients (51.9%, SOP- group) had not received either 1) or 2). There were no significant differences in baseline characteristics and prior-existing medical conditions between groups, however, significantly more patients in SOP- group were treated in emergency settings (39.9% vs. 21.7%, p=0.004). However, significantly more patients in SOP- were treated in emergency settings at higher risk (39.9% (SOP-) vs. 21.7% (SOP+); p<0.001). In univariate analysis, all in-hospital clinical outcomes of mortality (1.4% (SOP+) vs. 5.8% (SOP-); p=0.016), MB (2.9% (SOP+) vs. 9.9% (SOP-); p=0.003) and AKI were significantly lower in the SOP+ group (15.9% (SOP+) vs. 24.2% (SOP-); p=0.033). After correction for the difference in risk between groups due to emergency settings by multivariate logistic regression analysis, MB remained significantly lower in SOP+ (p=0.02), while mortality (p=0.14) and AKI (p=0.19) were not significantly associated with SOP-status anymore.
Conclusion
Standardized risk management in invasively managed NSTEMI was associated with significantly lower rates of in-hospital major bleedings.
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Junior Clinician Scientist Track, Medical faculty, Heinrich-Heine-University Düsseldorf, Germany
Collapse
Affiliation(s)
- J Troestler
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - C Parco
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - M Brockmeyer
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - Y Lin
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - T Krieger
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - J Quade
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - S Bader
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - L Kosejian
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - A Karathanos
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - Y Heinen
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - V Schulze
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - A Icks
- Heinrich Heine University, Institute for Health Services Research and Health Economics, Centre for Health and Society, Duesseldorf, Germany
| | - M Kelm
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - G Wolff
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| |
Collapse
|
8
|
Duan S, Feng X, Gonzalez M, Bader S, Hayward C, Ljubicic T, Lu J, Mustakis J, Maloney M, Rainville J, Zhang X. Developing a Multistep Continuous Manufacturing Process for (1R,2R)-2-Amino-1-methylcyclopentan-1-ol. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00405] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Shengquan Duan
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xichun Feng
- Asymchem Life Science (Tianjin) Co., Ltd., No. 71, 7th Avenue, TEDA, Tianjin 300457, P. R. China
| | - Miguel Gonzalez
- Asymchem Inc., 600 Airport Blvd. Suite 1000, Morrisville, North Carolina 27516, United States
| | - Scott Bader
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cheryl Hayward
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tomislav Ljubicic
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jiangping Lu
- Asymchem Life Science (Tianjin) Co., Ltd., No. 71, 7th Avenue, TEDA, Tianjin 300457, P. R. China
| | - Jason Mustakis
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark Maloney
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Joseph Rainville
- Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xin Zhang
- Asymchem Life Science (Tianjin) Co., Ltd., No. 71, 7th Avenue, TEDA, Tianjin 300457, P. R. China
| |
Collapse
|
9
|
Wolff G, Lin Y, Quade J, Bader S, Kosejian L, Karathanos A, Brockmeyer M, Heinen Y, Kelm M, Schulze V. P6355Validation of an NCDR-score-based risk model for cardiac catheterization procedures in a european population. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G Wolff
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - Y Lin
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - J Quade
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - S Bader
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - L Kosejian
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - A Karathanos
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - M Brockmeyer
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - Y Heinen
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - M Kelm
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| | - V Schulze
- University Hospital Dusseldorf, Cardiology, Pulmonology and Angiology, Dusseldorf, Germany
| |
Collapse
|
10
|
Bader S, Faul C, Raab S, Schwaiblmair M, Berghaus TM. Erfolgreiche Fistelokklusion mittels Endobronchialventilen bei therapierefraktärem Spontanpneumothorax bei Pneumocystis jiroveci-Pneumonie. Pneumologie 2018. [DOI: 10.1055/s-0037-1619232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Bader
- I. Medizinische Klinik, Klinikum Augsburg
| | - C Faul
- I. Medizinische Klinik, Klinikum Augsburg
| | - S Raab
- Klinik für Herz- und Thoraxchirurgie, Klinikum Augsburg
| | | | | |
Collapse
|
11
|
Li H, Sheeran JW, Clausen AM, Fang YQ, Bio MM, Bader S. Flow Asymmetric Propargylation: Development of Continuous Processes for the Preparation of a Chiral β-Amino Alcohol. Angew Chem Int Ed Engl 2017; 56:9425-9429. [DOI: 10.1002/anie.201704882] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Hui Li
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | | | | | - Yuan-Qing Fang
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | - Matthew M. Bio
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | - Scott Bader
- Chemical R&D; Pfizer Worldwide R&D; Eastern Point Road, MS 8118D-4047 Groton CT 06340 USA
| |
Collapse
|
12
|
Li H, Sheeran JW, Clausen AM, Fang YQ, Bio MM, Bader S. Flow Asymmetric Propargylation: Development of Continuous Processes for the Preparation of a Chiral β-Amino Alcohol. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201704882] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Hui Li
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | | | | | - Yuan-Qing Fang
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | - Matthew M. Bio
- Snapdragon Chemistry Inc.; 85 Bolton St. Cambridge MA 02140 USA
| | - Scott Bader
- Chemical R&D; Pfizer Worldwide R&D; Eastern Point Road, MS 8118D-4047 Groton CT 06340 USA
| |
Collapse
|
13
|
Bader S, Zajac M, Friess T, Ruge E, Rieder N, Gierke B, Heubach Y, Thomas M, Pawlak M. Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32933-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
|
15
|
Futatsugi K, Kung DW, Orr STM, Cabral S, Hepworth D, Aspnes G, Bader S, Bian J, Boehm M, Carpino PA, Coffey SB, Dowling MS, Herr M, Jiao W, Lavergne SY, Li Q, Clark RW, Erion DM, Kou K, Lee K, Pabst BA, Perez SM, Purkal J, Jorgensen CC, Goosen TC, Gosset JR, Niosi M, Pettersen JC, Pfefferkorn JA, Ahn K, Goodwin B. Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J Med Chem 2015; 58:7173-85. [DOI: 10.1021/acs.jmedchem.5b01006] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Kentaro Futatsugi
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Daniel W. Kung
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Shawn Cabral
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Gary Aspnes
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Scott Bader
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jianwei Bian
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Philip A. Carpino
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Steven B. Coffey
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Matthew S. Dowling
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Michael Herr
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Sophie Y. Lavergne
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Qifang Li
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Ronald W. Clark
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Derek M. Erion
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kou Kou
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kyuha Lee
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Brandon A. Pabst
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Sylvie M. Perez
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Julie Purkal
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Csilla C. Jorgensen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Theunis C. Goosen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - James R. Gosset
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Mark Niosi
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - John C. Pettersen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jeffrey A. Pfefferkorn
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kay Ahn
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Bryan Goodwin
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| |
Collapse
|
16
|
Arsalan M, Bader S, Baumgarten H, Blumenstein J, Mollmann H, Troidl C, Walther T, Kempfert J. 075-I * PRESSURE-CONTROLLED VEIN GRAFT FLUSHING RESULTS IN SUPERIOR HISTOLOGICAL QUALITY: A RANDOMISED TRIAL. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu276.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Arsalan M, Kempfert J, Bader S, Arsalan-Werner A, Blumenstein J, Troidl C, Möllmann H, Walther T. Pressure controlled vein graft flushing results in superior histological quality - a randomized trial. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Yaniv G, Bader S, Lidar M, Herman A, Shazar N, Aharoni D, Eshed I. The natural course of bridging osteophyte formation in diffuse idiopathic skeletal hyperostosis: retrospective analysis of consecutive CT examinations over 10 years. Rheumatology (Oxford) 2013; 53:1951-7. [DOI: 10.1093/rheumatology/ket335] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Panke C, Weininger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel H, Baer U, Burtscher H, Mundigl O, Grote M, Brinkmann U, Sustmann C. Quantification of cell surface proteins with bispecific antibodies. Protein Eng Des Sel 2013; 26:645-54. [PMID: 23960142 PMCID: PMC3785250 DOI: 10.1093/protein/gzt035] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Revised: 06/03/2013] [Accepted: 06/27/2013] [Indexed: 11/28/2022] Open
Abstract
Flow cytometry is an established method for fast and accurate quantitation of cellular protein levels and requires fluorescently labeled antibodies as well as calibration standards. A critical step for quantitation remains the production of suitable detection antibodies with a precisely defined ratio of antigen-binding sites to fluorophores. Problems often arise as a consequence of inefficient and unspecific labeling which can influence antibody properties. In addition, the number of incorporated fluorophores necessitates a special normalization step for quantitation. To address these problems, we constructed different mono- and bivalent bispecific antibodies with binding site(s) for the cell surface antigens, cMET, EGFR1/HER1, ErbB2/HER2 or ErbB3/HER3 and with an additional digoxigenin-binding single-chain Fv fusion. The fluorophore Cy5 was covalently coupled to digoxigenin and quantitatively bound by the bispecific antibody. A panel of tumor cell lines was assessed under different culture conditions for absolute receptor expression levels of the indicated antigens and the data were set in relation to mRNA, gene count and immunoblot data. We could reproducibly quantify these receptors, omit the otherwise required normalization step and demonstrate the superiority of a 1 + 1 bispecific antibody. The same antibodies were also used to quantify the number of proteins in intracellular vesicles in confocal microscopy. The antibodies can be stored like regular antibodies and can be coupled with different digoxigenin-labeled fluorophores which makes them excellent tools for FACS and imaging-based experiments.
Collapse
Affiliation(s)
- C. Panke
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - D. Weininger
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - A. Haas
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - F. Schelter
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - T. Schlothauer
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - S. Bader
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - R. Sircar
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - H.P. Josel
- Roche Professional Diagnostic, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - U. Baer
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - H. Burtscher
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - O. Mundigl
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - M. Grote
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - U. Brinkmann
- Roche Large Molecule Research, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - C. Sustmann
- Roche Pharma Research & Early Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| |
Collapse
|
20
|
Schütz B, Bader S, Ringer C, Gäckler C, Krasteva-Christ G, Kummer W, Diener M, Weihe E. The cholinergic phenotype and responsiveness of brush cells in the mouse digestive tract. Auton Neurosci 2013. [DOI: 10.1016/j.autneu.2013.05.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Bader S, Klein J, Diener M. Expression and function of non-neuronal acetylcholine in rat colonic epithelium. Auton Neurosci 2013. [DOI: 10.1016/j.autneu.2013.05.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Yaniv G, Portnoy O, Simon D, Bader S, Konen E, Guranda L. Revised protocol for whole-body CT for multi-trauma patients applying triphasic injection followed by a single-pass scan on a 64-MDCT. Clin Radiol 2013; 68:668-75. [DOI: 10.1016/j.crad.2012.12.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2012] [Revised: 12/23/2012] [Accepted: 12/27/2012] [Indexed: 11/16/2022]
|
23
|
Freeman-Cook KD, Amor P, Bader S, Buzon LM, Coffey SB, Corbett JW, Dirico KJ, Doran SD, Elliott RL, Esler W, Guzman-Perez A, Henegar KE, Houser JA, Jones CS, Limberakis C, Loomis K, McPherson K, Murdande S, Nelson KL, Phillion D, Pierce BS, Song W, Sugarman E, Tapley S, Tu M, Zhao Z. Maximizing Lipophilic Efficiency: The Use of Free-Wilson Analysis in the Design of Inhibitors of Acetyl-CoA Carboxylase. J Med Chem 2012; 55:935-42. [DOI: 10.1021/jm201503u] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Kevin D. Freeman-Cook
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Paul Amor
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Scott Bader
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Leanne M. Buzon
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Steven B. Coffey
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Jeffrey W. Corbett
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Kenneth J. Dirico
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Shawn D. Doran
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Richard L. Elliott
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - William Esler
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Angel Guzman-Perez
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Kevin E. Henegar
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Janet A. Houser
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Christopher S. Jones
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Katherine Loomis
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Kirk McPherson
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Sharad Murdande
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Kendra L. Nelson
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Dennis Phillion
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Betsy S. Pierce
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Wei Song
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Eliot Sugarman
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Susan Tapley
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Meihua Tu
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| | - Zhengrong Zhao
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut
06340, United States
| |
Collapse
|
24
|
Jamieson A, Bader S, Meakin G, Mullen C. Two-, three-, and four-person mixtures in forensic casework: difficulties and questions. Croat Med J 2011; 52:653-4; author reply 654-6. [PMID: 21990086 PMCID: PMC3195977 DOI: 10.3325/cmj.2011.52.653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
25
|
Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol 2011; 5:201-11. [PMID: 21836816 PMCID: PMC3153119 DOI: 10.4137/cmo.s4867] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Constipation, one of the major side effects of opiates used in palliative care, can impair patients’ quality of life to a point where it prevents sufficient pain control. Methylnaltrexone is a novel μ-receptor antagonist, which does not pass the blood brain barrier. It is licensed to treat opiate induced constipation for patients with advanced diseases. This review article presents an overview of pharmacology and safety of its application, evidence of its efficacy and economic aspects of its use in clinical practice. Available data are limited but strongly suggest that methylnaltrexone causes laxation in less than 24 hours for at least half of those patients over the first two weeks of usage without impairing pain control or causing serious adverse effects. To avoid danger of gastrointestinal perforation it is contraindicated for patients at risk for that complication. More research is needed to evaluate its long-term efficacy and economic impact.
Collapse
Affiliation(s)
- S Bader
- Department of Palliative Care, University Hospital Freiburg, Robert-Koch-Str. 3, D-79106, Freiburg
| | | | | | | |
Collapse
|
26
|
Abstract
AbstractThe substrate curvature technique was employed to study the mechanical properties of 0.6 μm and 1.0 μm Cu films capped with a 50 nm thick Si3N4 layer and to compare them with the mechanical properties of uncapped Cu films. The microstructures of these films were also investigated. Grain growth, diffusional creep and dislocation processes are impeded by the cap layer. This is evident in the form of high stresses at high temperatures on heating and at low temperatures on cooling. At intermediate temperatures on heating and cooling, stress plateaus a relatively low stresses exist. This can be explained by the so-called Bauschinger effect. A film thickness dependence of the stresses in the film could not be observed for capped Cu films.
Collapse
|
27
|
Kraft O, Bader S, Sanchez J, Arzt E. Observation and Modelling of Electromigration-Induced Void growth in Al-Based Interconnects. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-309-199] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractAccelerated electromigation tests on unpassivated, pure aluminum interconnects were performed. The failure mechanisms were observed by interrupting the tests and exanming the conductor lines using an SEM. Because the metal thin film was subjected to a so-called laser reflow process before patterning, grain boundaries were visible in the SEM as thermal grooves. Voids were observed to move along the line and to grow in a transgranular manner, and a characteristic asymmetric void shape was identified which seems to be related to the failure mechanism. It is argued that substantial progress in modelling and understanding of electromigration failure can be made by consideration of such void shape effects.
Collapse
|
28
|
Keller RM, Kuschke WM, Kretschmann A, Bader S, Vinci R, Arzt E. Influence of Film Thickness and Capping Layer on the Mechanical Properties of Copper Films. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-391-309] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractSubstrate curvature and X-ray technique were used to study the mechanical properties of Cu films. Stress-temperature curves were measured using both methods. An additional analysis of the X-ray peak width allows us to estimate grain size and dislocation density as a function of temperature. It can be shown that a capping layer changes the mechanical properties of a Cu film strongly and that in capped films dislocation processes seem to be more important than diffusion at high temperatures.
Collapse
|
29
|
Streiffer SK, Bader S, Deininger C, Mayer J, Rühle M. Measurement of Thermally-Induced Strains in Polycrystalline Al Thin Films on Si Using Convergent Beam Electron Diffraction. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-343-615] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTStrains in polycrystalline Al films grown on oxidized Si wafers were measured using convergent beam electron diffraction (CBED). CBED patterns were acquired on a Zeiss EM 912 TEM equipped with an imaging energy filter and CCD camera. HOLZ line positions in the (000) CBED disk were matched using an automated refinement procedure. A sensitivity to variations in lattice parameter of approximately 0.00007 nm was obtained. Strong deviations from a simple equibiaxial strain, perfect [111] texture model were observed.
Collapse
|
30
|
Kraft O, Bader S, Sanchez J, Arzt E. Observation and Modelling of Electromigration-Induced Void Growth In AI-Based Interconnects. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-308-267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTAccelerated electromigation tests on unpassivated, pure aluminum interconnects were performed. The failure mechanisms were observed by interrupting the tests and examining the conductor lines using an SEM. Because the metal thin film was subjected to a so-called laser reflow process before patterning, grain boundaries were visible in the SEM as thermal grooves. Voids were observed to move along the line and to grow in a transgranular manner, and a characteristic asymmetric void shape was identified which seems to be related to the failure mechanism. It is argued that substantial progress in modelling and understanding of electromigration failure can be made by consideration of such void shape effects.
Collapse
|
31
|
Bunkowski A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbach JI. MCC/IMS signals in human breath related to sarcoidosis—results of a feasibility study using an automated peak finding procedure. J Breath Res 2009; 3:046001. [DOI: 10.1088/1752-7155/3/4/046001] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
32
|
Bunkowski A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbach JI. Signals in human breath related to Sarcoidosis. — Results of a feasibility study using MCC/IMS. ACTA ACUST UNITED AC 2009. [DOI: 10.1007/s12127-009-0022-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 2009; 64:744-8. [DOI: 10.1136/thx.2008.099465] [Citation(s) in RCA: 191] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Ahmad VU, Bader S, Arshad S, Iqbal S, Ahmed A, Mohammad FV, Khan A, Kann A, Tareen RB. A new acylated flavone glycoside from the fruits of Stocksia brauhica. J Asian Nat Prod Res 2007; 9:299-305. [PMID: 17566925 DOI: 10.1080/10286020600727327] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Phytochemical investigations of the fruits of Stocksia brauhica (Sapindaceae) resulted in the isolation of a new acylated flavone glycoside. Its structure of the new compound brauhenefloroside D (1) was established as 3-O-[(alpha-L-rhamnopyranosyl)oxy]-7-O-[(acetyl)-beta-D-glucopyranosyl (1 --> 4)]-[6-O-(4-hydroxy-E-cinnamoyl)-beta-D-glucopyranosyl-(1 --> 2)-alpha-L-rhamnopyranosyl)-oxy]-kaempferol. The structure elucidation of the new compound was based primarily on 1D and 2D NMR analysis, including COSY, HMBC and HMQC correlations.
Collapse
Affiliation(s)
- V U Ahmad
- International Centre for Chemical Sciences, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi 75270, Pakistan.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Owen R, Baker R, Bader S, Dunlop M, Nicholl I. The identification of a novel alternatively spliced form of the MBD4 DNA glycosylase. Oncol Rep 2007. [DOI: 10.3892/or.17.1.111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
36
|
Owen RM, Baker RD, Bader S, Dunlop MG, Nicholl ID. The identification of a novel alternatively spliced form of the MBD4 DNA glycosylase. Oncol Rep 2007; 17:111-6. [PMID: 17143486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023] Open
Abstract
Methyl-CpG binding protein 4 (MBD4) is a mismatch-specific G:T and G:U DNA glycosylase. During an analysis of MBD4 expression in HeLa cells we noted the presence of an unexpectedly short reverse transcribed product. This cDNA lacked the region encoding the methyl-binding domain and exon 3 of MBD4 but retained the glycosylase domain. Sequence comparison indicates the existence of a previously unreported cryptic splice site in the MBD4 genomic sequence thus illuminating a mechanism whereby a glycosylase acquired a methyl-binding capacity, thus targeting potential mutagenic CpG sites. In vitro assays of this highly purified species, refolded in arginine rich conditions, confirmed that this unique, short version of MBD4 possessed uracil DNA glycosylase but not thymine DNA glycosylase activity. We conclude that the identification of a transcript encoding a short version of MBD4 indicates that MBD4 expression may be more complex than previously reported, and is worthy of further investigation.
Collapse
Affiliation(s)
- Rhiannon M Owen
- Research Institute in Healthcare Science, School of Applied Sciences, University of Wolverhampton, Wolverhampton WV1 1SB, UK
| | | | | | | | | |
Collapse
|
37
|
Bader S, Heister K. The effect of membrane potential on the development of chemical osmotic pressure in compacted clay. J Colloid Interface Sci 2006; 297:329-40. [PMID: 16289192 DOI: 10.1016/j.jcis.2005.10.036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Revised: 10/08/2005] [Accepted: 10/11/2005] [Indexed: 10/25/2022]
Abstract
When clay soils are subjected to salt concentration gradients, various interrelated processes come into play. It is known that chemical osmosis induces a water flow and that a membrane potential difference develops that counteracts diffusive flow of solutes and osmotic flow of water. In this paper, we present the results of experiments on the influence of membrane potential on chemical osmotic flow and diffusion of solutes and we show how we are able to derive the membrane potential value from theory. Moreover, the simultaneous development of water pressure, salt concentration and membrane potential difference are simulated using a model for combined chemico-electroosmosis in clays. A new method for short-circuiting the clay sample is employed to assess the influence of electrical effects on flow of water and transport of solutes.
Collapse
Affiliation(s)
- S Bader
- Environmental Hydrogeology Group, Faculty of Geosciences, Department of Earth Sciences, Utrecht University, PO Box 80021, 3508TA, Utrecht, The Netherlands.
| | | |
Collapse
|
38
|
Westhoff M, Litterst P, Ruzsanyi V, Bader S, Urfer W, Baumbach J, Freitag L. Ionenmobilitätsspektrometrie – eine neue Methode zur Detektion von Bronchialkarzinomen und Atemwegsinfektionen in der Ausatemluft? Erste Resultate einer Pilotstudie. Pneumologie 2006. [DOI: 10.1055/s-2006-934029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Aicher D, Langer F, Goege A, Bader S, Lausberg H, Schäfers HJ. Mitral valve repair for anterior and bileaflet leaflet prolapse – a safe option? Thorac Cardiovasc Surg 2005. [DOI: 10.1055/s-2005-922389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
40
|
De Preter K, Vandesompele J, Menten B, Carr P, Fiegler H, Edsjö A, Carter NP, Yigit N, Waelput W, Van Roy N, Bader S, Påhlman S, Speleman F. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics 2005; 6:97. [PMID: 16000168 PMCID: PMC1185534 DOI: 10.1186/1471-2164-6-97] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2005] [Accepted: 07/06/2005] [Indexed: 11/10/2022] Open
Abstract
Background Loss of chromosome 11q defines a subset of high-stage aggressive neuroblastomas. Deletions are typically large and mapping efforts have thus far not lead to a well defined consensus region, which hampers the identification of positional candidate tumour suppressor genes. In a previous study, functional evidence for a neuroblastoma suppressor gene on chromosome 11 was obtained through microcell mediated chromosome transfer, indicated by differentiation of neuroblastoma cells with loss of distal 11q upon introduction of chromosome 11. Interestingly, some of these microcell hybrid clones were shown to harbour deletions in the transferred chromosome 11. We decided to further exploit this model system as a means to identify candidate tumour suppressor or differentiation genes located on chromosome 11. Results In a first step, we performed high-resolution arrayCGH DNA copy-number analysis in order to evaluate the chromosome 11 status in the hybrids. Several deletions in both parental and transferred chromosomes in the investigated microcell hybrids were observed. Subsequent correlation of these deletion events with the observed morphological changes lead to the delineation of three putative regions on chromosome 11: 11q25, 11p13->11p15.1 and 11p15.3, that may harbour the responsible differentiation gene. Conclusion Using an available model system, we were able to put forward some candidate regions that may be involved in neuroblastoma. Additional studies will be required to clarify the putative role of the genes located in these chromosomal segments in the observed differentiation phenotype specifically or in neuroblastoma pathogenesis in general.
Collapse
Affiliation(s)
- Katleen De Preter
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Jo Vandesompele
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Björn Menten
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Philippa Carr
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
| | - Heike Fiegler
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
| | - Anders Edsjö
- Department of Laboratory Medicine, Molecular Medicine, Lund University, University Hospital MAS, S-20502 Malmö, Sweden
| | - Nigel P Carter
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
| | - Nurten Yigit
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Wim Waelput
- Department of Pathological Anatomy, Ghent University Hospital BLOK A, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Nadine Van Roy
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| | - Scott Bader
- Sir Alastair Currie Cancer Research U.K. Laboratories, Division of Pathology, Molecular Medicine Centre, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, United Kingdom
| | - Sven Påhlman
- Department of Laboratory Medicine, Molecular Medicine, Lund University, University Hospital MAS, S-20502 Malmö, Sweden
| | - Frank Speleman
- Center for Medical Genetics, Ghent University Hospital MRB 2floor, De Pintelaan 185, B-9000 Ghent, Belgium
| |
Collapse
|
41
|
Abstract
The Hedgehog (Hh) signalling pathway is crucial for normal development and patterning of numerous human organs including the gut. Hh proteins are also expressed during gastric gland development and gastric epithelial differentiation in adults. Recently, dysregulation of these developmentally important genes has been implicated in cancer, leading to the present study of the expression of Hh signalling proteins in colon cancer. In this study, normal colon and colonic lesions (hyperplastic polyp, adenoma, and colonic adenocarcinoma) were examined by immunohistochemistry using antibodies against Hh signalling molecules: the secreted protein Sonic hedgehog (SHH), its receptor Patched (PTCH), and the PTCH-associated transmembrane protein Smoothened (SMOH). The study shows that Hh signalling pathway members are expressed in normal colonic epithelium. SHH was expressed at the top of the crypts and in a few basally located cells, while PTCH was detected in the neuroendocrine cells and SMOH at the brush border of superficial epithelium. RT-PCR analysis of laser-microdissected crypts from normal human colon confirmed that mRNAs encoding these proteins were expressed in colonic epithelium. Expression of SHH, PTCH, and SMOH was up-regulated in hyperplastic polyps, adenomas, and adenocarcinomas of the colon, and SHH expression correlated with increased expression of the proliferation marker Ki-67 in all lesions examined. To address whether the Hh signalling pathway is functional in the gut, the effect of Shh on epithelial cells in vitro was explored by treating primary murine colonocytes with either Shh peptide or neutralizing anti-Shh antibody. The proportion of cells in the S-phase was assessed by bromodeoxyuridine (BrdU) incorporation. It was found that exogenous Shh promotes cell proliferation in colonocytes, while anti-Shh inhibits proliferation, suggesting that Shh is required during proliferation of epithelial cells in vitro. It is suggested that SHH is required during epithelial proliferation in the colon and that there is a possible role for Hh signalling in epithelial colon tumour progression in vivo.
Collapse
Affiliation(s)
- Anca Oniscu
- Sir Alastair Currie Cancer Research UK Laboratories, Division of Pathology, Molecular Medicine Centre, University of Edinburgh, Crewe Road, Edinburgh, EH4 2XU, UK
| | | | | | | | | | | |
Collapse
|
42
|
Haerle V, Hahn B, Kaiser S, Weimar A, Bader S, Eberhard F, Plössl A, Eisert D. High brightness LEDs for general lighting applications Using the new ThinGaN™-Technology. ACTA ACUST UNITED AC 2004. [DOI: 10.1002/pssa.200405119] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
43
|
Oniscu A, Sphyris N, Morris RG, Bader S, Harrison DJ. p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes. J Clin Pathol 2004; 57:492-8. [PMID: 15113856 PMCID: PMC1770307 DOI: 10.1136/jcp.2003.012559] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
AIMS Colonocytes were derived from wild-type (wt) and p53 deficient mice to investigate p53 dependent and independent death pathways after cisplatin treatment, and the role of p53 in growth regulation of primary, untransformed epithelial cells. METHODS Wt and p53 null colonocytes were exposed to cisplatin and DNA synthesis, apoptosis, and p53, p21, and p73 expression were investigated after six, 12, and 24 hours. Major p73 isoforms were identified by reverse transcription polymerase chain reaction (RT-PCR). RESULTS Cisplatin treated wt cells exhibited cell cycle arrest, whereas p53 null cells continued to synthesise DNA, although both cell types died. Apoptosis was significantly higher in cisplatin treated wt and p53 null colonocytes than in controls at all timepoints, although apoptosis was lower in cisplatin treated p53 null colonocytes than in wt cells. p53 expression was upregulated in cisplatin treated wt colonocytes. p21 expression was high and remained unchanged in cisplatin treated wt cells, although it was reduced in the absence of p53. p73 was investigated because it could account for p53 independent p21 expression and p53 independent death. RT-PCR detected full length p73alpha. p73 transcript levels remained unchanged, whereas p73 protein accumulated in the nucleus of cisplatin treated cells, irrespective of genotype. CONCLUSIONS p53 is essential for cell cycle arrest, but not apoptosis in primary murine colonocytes. Apoptosis is reduced in cisplatin treated p53 null cells. Nuclear accumulation of endogenous p73 after cisplatin treatment suggests a proapoptotic role for p73alpha in the absence of p53 and collaboration with p53 in wt colonocytes.
Collapse
Affiliation(s)
- A Oniscu
- Sir Alastair Currie Cancer Research UK Laboratories, Division of Pathology, Molecular Medicine Centre, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK
| | | | | | | | | |
Collapse
|
44
|
Bader S, Walker M, McQueen HA, Sellar R, Oei E, Wopereis S, Zhu Y, Peter A, Bird AP, Harrison DJ. MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 2003; 22:3506-10. [PMID: 12776203 DOI: 10.1038/sj.onc.1206574] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5'-DCC 3'-MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.
Collapse
Affiliation(s)
- Scott Bader
- Sir Alastair Currie Cancer Research UK Laboratories, Division of Pathology Molecular Medicine Centre, University of Edinburgh, Edinburgh EH4 2XU, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Vehse M, Meinertz J, Lange O, Michler P, Gutowski J, Bader S, Lell A, Härle V. Analysis of Gain Saturation Behavior in GaN Based Quantum Well Lasers. ACTA ACUST UNITED AC 2002. [DOI: 10.1002/pssc.200390083] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Vehse
- Institut für Festkörperphysik, Universität Bremen, 28334 Bremen, Germany
| | - J. Meinertz
- Institut für Festkörperphysik, Universität Bremen, 28334 Bremen, Germany
| | - O. Lange
- Institut für Festkörperphysik, Universität Bremen, 28334 Bremen, Germany
| | - P. Michler
- Institut für Festkörperphysik, Universität Bremen, 28334 Bremen, Germany
| | - J. Gutowski
- Institut für Festkörperphysik, Universität Bremen, 28334 Bremen, Germany
| | - S. Bader
- Osram Optosemiconductors GmbH & Co OHG, 93049 Regensburg, Germany
| | - A. Lell
- Osram Optosemiconductors GmbH & Co OHG, 93049 Regensburg, Germany
| | - V. Härle
- Osram Optosemiconductors GmbH & Co OHG, 93049 Regensburg, Germany
| |
Collapse
|
46
|
Hsiao CC, Su WN, Forooghian F, Bader S, Rempel J, HayGlass KT, Gilman A, Schultz KR. Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. Bone Marrow Transplant 2002; 30:905-13. [PMID: 12476284 DOI: 10.1038/sj.bmt.1703727] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2002] [Accepted: 06/12/2002] [Indexed: 11/09/2022]
Abstract
The 4-aminoquinolines, chloroquine and hydroxychloroquine, can suppress chronic graft-versus-host disease (GVHD) following blood and marrow transplantation (BMT) in mice and humans, respectively. We hypothesized that chloroquine in combination with tacrolimus and the rapamycin derivative SDZ-RAD can synergistically suppress T cell responses and antigen-presenting cell (APC) function in vitro. We used the APC-dependent C57BL/6 anti-BALB.B T cell response and APC-independent anti-CD3epsilon antibody-induced response to evaluate the role of synergism between chloroquine and tacrolimus or SDZ-RAD on each component of a T cell response to minor histocompatibility antigens. We found that chloroquine with tacrolimus had a greater synergistic suppression of APC-dependent compared to the APC-independent T cell responses, with a combination index (CIx) for 50% inhibition by mean effect analysis of 0.16 and 0.50, respectively (a lower number indicates greater suppression). By contrast, chloroquine with SDZ-RAD had a similar CIx between the two responsed 0.50 vs0.45) suggesting only T cell suppression. Synergy between chloroquine and SDZ-RAD involved a direct effect on T cell cytokine production, whereas synergism between chloroquine and tacrolimus was due to an effect on both T cells and APCs. We conclude that the renal-sparing 4-aminoquinolines may be used syneristically with immunosuppressive drugs currently used for BMT.
Collapse
Affiliation(s)
- C-C Hsiao
- Department of Pediatric Hematology and Oncology, Chang Gung Children's Hospital, Kaohsiung, Taiwan, ROC
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Wong NACS, Morris RG, McCondochie A, Bader S, Jodrell DI, Harrison DJ. Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol 2002; 197:128-35. [PMID: 12081197 DOI: 10.1002/path.1113] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Cyclin D1 protein overexpression is commonly found in colorectal carcinomas (CRCs) and is associated with a poorer prognosis, but the mechanism underlying overexpression remains uncertain. Both dysregulation of beta-catenin protein expression and k-ras mutation have recently been shown to promote cyclin D1 expression in human in vitro and rodent in vivo studies. In this study, 53 sporadic CRCs were examined by immunohistochemistry for cyclin D1 and beta-catenin protein expression, and with PCR and direct DNA sequencing for k-ras gene status. The study also addressed whether cyclin Dl overexpression might associate with poorer prognosis because of a relationship with poorer response to 5-fluorouracil (5FU) chemotherapy. Cyclin D1 overexpression was demonstrated in 34/53 (64%) CRCs, was significantly associated with higher Dukes' stage, and was particularly prominent at the invasive edges of carcinomas. Furthermore, cyclin D1 overexpression was always and only seen in association with nuclear expression of beta-catenin. There were no significant associations between cyclin D1 overexpression and k-ras mutation or response to 5FU. Amongst 17 microsatellite unstable CRCs, a smaller proportion of tumours showed cyclin D1 overexpression (18%), but again cyclin D1 overexpression was only seen in cases showing nuclear beta-catenin expression. In conclusion, beta-catenin protein dysregulation, but not k-ras mutation, appears to be required for cyclin D1 overexpression in colorectal carcinoma in vivo.
Collapse
Affiliation(s)
- N A C S Wong
- Department of Pathology, University of Edinburgh Medical School, UK.
| | | | | | | | | | | |
Collapse
|
48
|
Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691-9. [PMID: 11333291 PMCID: PMC4374741 DOI: 10.1093/jnci/93.9.691] [Citation(s) in RCA: 599] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The recently identified RASSF1 locus is located within a 120-kilobase region of chromosome 3p21.3 that frequently undergoes allele loss in lung and breast cancers. We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast cancers. METHODS We assessed expression of two RASSF1 gene products, RASSF1A and RASSF1C, and the methylation status of their respective promoters in 27 non-small-cell lung cancer (NSCLC) cell lines, in 107 resected NSCLCs, in 47 small-cell lung cancer (SCLC) cell lines, in 22 breast cancer cell lines, in 39 resected breast cancers, in 104 nonmalignant lung samples, and in three breast and lung epithelial cultures. We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line. All statistical tests were two-sided. RESULTS RASSF1A messenger RNA was expressed in nonmalignant epithelial cultures but not in 100% of the SCLC, in 65% of the NSCLC, or in 60% of the breast cancer lines. By contrast, RASSF1C was expressed in all nonmalignant cell cultures and in nearly all cancer cell lines. RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. RASSF1A promoter hypermethylation in resected NSCLCs was associated with impaired patient survival (P =.046). Exogenous expression of RASSF1A in a cell line lacking expression decreased in vitro colony formation and in vivo tumorigenicity. CONCLUSION RASSF1A is a potential tumor suppressor gene that undergoes epigenetic inactivation in lung and breast cancers through hypermethylation of its promoter region.
Collapse
Affiliation(s)
- D G Burbee
- Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, TX 75390-8593, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
The MBD4 gene is involved in the repair of mutation at methyl-CpG dinucleotides. In microsatellite unstable tumours MBD4 can itself be mutated at an exonic polynucleotide tract. By analysing DNA from microdissected tumour samples we have found that both frequency and pattern of mutation are more significant than originally reported.
Collapse
Affiliation(s)
- S Bader
- Sir Alastair Currie C.R.C. Laboratories, Department of Pathology, Molecular Medicine Centre, University of Edinburgh, Crewe Road, Edinburgh, EH4 2XU, UK
| | | | | |
Collapse
|
50
|
H�rle V, Hahn B, Lugauer HJ, Bader S, Br�derl G, Baur J, Eisert D, Strauss U, Zehnder U, Lell A, Hiller N. GaN-Based LEDs and Lasers on SiC. ACTA ACUST UNITED AC 2000. [DOI: 10.1002/1521-396x(200007)180:1<5::aid-pssa5>3.0.co;2-i] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|